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Background: ent-Sauchinone is a polyphenolic compound found in plants belonging to the lignan family.
ent-Sauchinone has been shown to modulate the expression of inflammatory factors through the nuclear factor-kappa
B (NF-κB) signaling pathway. It is well known that neuroinflammation is associated with amyloidogenesis. Thus, in the
present study, we investigated whether ent-Sauchinone could have anti-amyloidogenic effects through the inhibition
of NF-κB pathways via its anti-inflammatory property.
Methods: To investigate the potential effect of ent-Sauchinone on anti-neuroinflammation and anti-amyloidogenesis
in in vitro studies, we used microglial BV-2 cells and cultured astrocytes treated with ent-Sauchinone (1, 5, and 10 μM)
for 24 hours. For the detection of anti-neuro-inflammatory responses, reative oxygen species (ROS) and Nitric oxide
(NO) generation and inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression were measured
with assay kits and western blotting. β-secretase and β-secretase activities and β-amyloid levels were determined for
measuring the anti-amyloidogenic effects of ent-Sauchinone by enzyme assay kits. NF-κB and STAT3 signals were
detected with electromobility shift assay (EMSA) to study the related signaling pathways. The binding of
ent-Sauchinone to STAT3 was evaluated by a pull-down assay and by a docking model using Autodock VINA
software (Hoover’s Inc., Texas, United states).
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Results: ent-Sauchinone (1, 5, and 10 μM) effectively decreased lipopolysaccharide (LPS)-(1 μg/ml) induced
inflammatory responses through the reduction of ROS and NO generations and iNOS and COX-2 expressions
in cultured astrocytes and microglial BV-2 cells. ent-Sauchinone also inhibited LPS-induced amyloidogenesis
through the inhibition of β-secretase and β-secretase activity. NF- κB amyloid and STAT3, critical transcriptional
factors regulating not only inflammation but also amyloidogenesis, were also inhibited in a concentration
dependent manner by ent-Sauchinone by blocking the phosphorylation of I κB and STAT3 in cultured
astrocytes and microglial BV-2 cells. The docking model approach showed that ent-Sauchinone binds to STAT3,
and the employment of a STAT3 inhibitor and siRNA reversed ent-Sauchinone-induced inhibition NF-κB
activation and Aβ generation.
Conclusions: These results indicated that ent-Sauchinone inhibited neuroinflammation and amyloidogenesis
through the inhibition of STAT3-mediated NF-κB activity, and thus could be applied in the treatment of
neuro-inflammatory diseases, including Alzheimer’s disease.
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Alzheimer’s disease (AD) is an age-related neurodegen-
erative disease characterized by the accumulation of beta
amyloid (A), an insoluble peptide deposited extracellu-
larly in the brain, causing senile plaques [1]. This hydro-
phobic polypeptide is the product of proteolytic cleavage
of the amyloid precursor protein (APP). Brains of AD
patients exhibit a number of pathological abnormalities
including a profound loss of synapses, microglial activa-
tion, and inflammatory processes [2]. Inflammatory reac-
tions and mediators have been reported to augment APP
expression and A formation [3,4] and transcriptionally
up-regulate mRNA, protein levels, and enzymatic activ-
ity of β-secretase, a key enzyme in the production of A
[5]. Recently, we and other researchers have also shown
that anti-inflammatory agents prevent A deposition [6,7]
and that anti-inflammatory agents prevent A deposition
in cultured neuronal cells [7-9] as well as in mouse models
of AD [7,10]. Moreover, McGeer et al. suggested that anti-
inflammatory agents could be applicable for the treatment
of patients with AD [11]. These observations strongly sug-
gest that anti-inflammatory agents could be effective for
the prevention of AD prevalence through the reduction of
A generation and/or deposition [12].
In most neurodegenerative disorders, massive neuronal
cell death occurs as a consequence of an uncontrolled
neuro-inflammatory response by the activation of astro-
cytes and microglia [13]. Glial cells such as astrocytes and
microglia can induce cytokines, reactive oxygen radicals
(ROS), and nitric oxide (NO) which lead to exaggeration
of the disease processes [14]. Expression of inducible nitric
oxide synthase (iNOS) and cyclooxygenase-2 (COX-2)
can be regulated by the activation of nuclear factor-κB
(NF-κB) because there is one NF-κB DNA consensus se-
quence within the COX-2 promoter [15], and two NF-κB
DNA consensus sequences within the iNOS promoter
[16]. Moreover, NF-κB DNA consensus sequences are alsolocated in the promoter of neuronal β-secretase (BACE 1).
Thus, dysregulation of NF-κB would provide a potential
approach for the management of AD through the reduc-
tion of both neuroinflammation and A generation [17].
Signal transducer and activator of transcription 3 (STAT3)
is also a significant regulator of neuroinflammation and
A generation [18]. We demonstrated that inactivation
of STAT3 inhibited A generation and neuroinflamma-
tion through the suppression of NF-κB activation. [19].
Sauchinone is reported to perform a variety of biological
activities such as hepatoprotective, anti-inflammatory ac-
tions and inhibitory effects on bone resorption [20].
However, it is not clear yet whether ent-Sauchinone could
show an anti-neuroinflammatory response and thus an
anti-amyloidogenic effect. In the present study, we investi-
gated anti-neuroinflammatory and anti-amyloidogenic ac-
tivities of ent-Sauchinone and its possible mechanisms in
cultured BV-2 cells and astrocytes.
Materials and methods
Chemicals and reagents
Cell culture mediums and agents such as Dulbecco’s
Modified Eagle’s Medium (DMEM, Invitrogen, Carlsbad,
California, United States), fetal bovine serum (FBS),
penicillin, streptomycin, Eagle’s salts, L-glutamine, pyru-
vate, potassium chloride (KCl), and antibiotics were pur-
chased from Invitrogen (Carlsbad, California, United
States) and trypsin was purchased from Sigma-Aldrich
(St Louis, Missouri, United States). Opti-MEM medium,
TRIzol reagent, Lipofectamine, and geneticin (G418)
were also acquired from Invitrogen (Carlsbad, California,
United States). siRNA and specific antibodies (rabbit poly-
clonal antibodies against p65 and I B and mouse monoclo-
nal antibody against p50) were obtained from Santa Cruz
Biotechnology Inc. (Santa Cruz, California, United States).
Rabbit polyclonal antibodies against iNOS and COX-2
were obtained from Cayman Chemical (1:1,000, Ann
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was purchased from Promega (Madison, Wisconsin,
United States). The -secretase activity kit was provided
from Abcam, Inc. (Cambridge, Massachusetts, United
States). An ELISA kit for A 1-42 level determination was
purchased from Immuno-Biological Laboratories Co.,
Ltd. (Tokyo, Japan). Cyanogen bromide Epoxy-activated
Sepharose 6B and all other chemicals were obtained
from Sigma-Aldrich (St Louis, Missouri, United States).
Preparation of ent-Sauchinone
The aerial parts of Saururus chinensis were purchased
from Kyungdong Oriental Herbal Market in Seoul,
Korea, September 2011 and identified by one of the
authors (BYH). A voucher specimen (CBNU-SC-2011)
has been deposited at the Herbarium of College of Phar-
macy, Chungbuk National University, Korea. The aerial
parts of S. chinensis (5.0 kg) were extracted with MeOH
three times (18 L × 3, overnight). The filtrate was evapo-
rated under reduced pressure to obtain a MeOH extract
(540 g), which was suspended in distilled water andFigure 1 Structural interaction between ent-Sauchinone and STAT3. e
(OAc)2 and tributyl phosphine (A). Pull-down assay identifies an interaction
conjugated with cyanogen bromide Epoxy-activated Sepharose 6B (B). Doc
and Methods (C and D).partitioned with n-hexane (40 g) and CH2Cl2 (100 g).
The CH2CI2-soluble fraction (100 g) was separated over
a silica gel column with a n-hexane-CH2CI2-MeOH
gradient to yield 20 fractions (SCC01-SCC20). Fraction
SCC-6 (0.5 g) was purified on a Sephadex LH-20
(CH2Cl2-MeOH, 1:1) and preparative HPLC (Waters
system, YMC (YMC CO., LTD., Kyoto, Japen) ODS
(octadecyl silane) H-80 column, 150 × 20 mm i.d (in-
ternal diameter), MeCN:H2O gradient, from 50:50 to
90:10, flow rate 6 mL/min) to obtain ent-Sauchinone
(50 mg). The structure of ent-Sauchinone (Figure 1A)
was determined by the comparison of its physicochemi-
cal and spectroscopic data as reported previously [20].
ent-Sauchinone: Colorless needle crystal; [α]25D -110.8
o;
ESI-MS m/z 379 [M+Na]+; 1H-NMR (CDCl3, 500 MHz)
δH 6.86 (1H, s, H-6), 6.45 (1H, s, H-3), 5.95 (1H, br d, J =
1.5 Hz, H-10a), 5.91 (1H, br d, J = 1.5 Hz, H-10b), 5.69
(1H, s, H-10’a), 5.64 (1H, s, H-10’b), 5.54 (1H, s, H-3’),
3.07 (1H, d, J = 5.3 Hz, H-7), 2.54 (1H, m, H-1’), 2.52 (1H,
d, J = 5.3 Hz, H-6’), 2.48 (1H, m, H-8), 1.94 (1H, dt, J =
13.0, 3.4 Hz, H-7’a), 1.66 (1H, m, H-7’b), 1.92 (1H, m,nt-Sauchinone was prepared from 4-(oxiran-2-yl) phenyl acetate, Pd
between the ent-Sauchinone and STAT3. ent-Sauchinone was
king model of ent-Sauchinone with STAT3 as described in Materials
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7.5 Hz, H-9’); 13C-NMR (CDCl3, 125 MHz) δ C 115.6 (C-1),
144.9 (C-2), 99.1 (C-3), 143.1 (C-4), 146.6 (C-5), 106.4
(C-6), 34.9 (C-7), 34.7 (C-8), 21.2 (C-9), 37.4 (C-1’),
199.5 (C-2’), 100.1 (C-3’), 168.5 (C-4’), 100.3 (C-5’), 37.5
(C-6’), 25.1 (C-7’), 33.3 (C-8’), 20.8 (C-9’), 101.2
(OCH2O), 98.5 (OCH2O).
BV-2 cell culture
BV-2 cells were obtained from the American Type Culture
Collection (Rockville, Maryland, United States). These
cells were maintained at subconfluence in a 95% air/5%
CO2 humidified atmosphere at 37°C. The medium used
for routine subcultivation was DMEM (Invitrogen, Carlsbad,
California, United States), supplemented with 10% FBS,
penicillin (100 units/ml), and streptomycin (100 μg/ml).
Cells were counted with a hemocytometer and the num-
ber of viable cells was determined through trypan blue
dye exclusion.
Astrocyte culture
Sprague-Dawley rats were maintained in accordance
with the policy of the National Institute of Toxicological
Research, which is in accordance with the Korea Food
and Drug Administration’s guideline for the care and use
of laboratory animals. The Sprague-Dawley rats weighing
between 200 and 300 g were housed under 12 hour light/
dark cycles, at 23°C and 60 ± 5% humidity. All animals
had free access to food (Samyang Foods, Seoul, Korea)
and water. Cerebral cortical cells were isolated from the
neonatal rat brains (day 1) in PBS (0.1 mol). After washing
with DMEM, the isolated cells were incubated for 15 minutes
in DMEM containing 0.2% trypsin. Cells were dissociated
by trituration and plated into polyethyleneimine-coated
plastic (5 × 105 cells/60 mm dish) containing minimum es-
sential medium with Eagle’s salts supplemented with 10%
heat-inactivated FBS, 2 mM L-glutamine, 1 mM pyruvate,
20 mM KCl, 10 mM sodium bicarbonate, and 1 mM
Hepes (pH 7.2). After three days in culture, the culture
medium was replaced with DMEM containing 10% FBS.
The culture medium was changed every three days.
Microglia and oligodendrocytes were isolated after the 12-
day culture by shaking off, then further incubated with
new DMEM with 10% FBS. The astrocytes were judged by
cell morphology and by immunostaining with antibodies
against glial fibrillary acidic protein (GFAP). Cells were
fixed in 4% paraformaldehyde, then incubated with the
antibody; GFAP (1:200 Cell Signaling Technology, Inc.,
Beverly, Massachusetts, United states), and visualized using
Alexa Fluor-conjugated secondary antibody (Life Technolo-
gies, Seoul, Korea). Nuclei were stained with 4′,6-diami-
dine-2-phenylindole dihydrochloride. Of the cells in the
astrocyte cultures, 95% were GFAP-positive. The astro-
cytes were more than 95%. The astrocytes were incubatedin the DMEM media with 10% FBS during treatment.
Cells grown on LabTek chamber slides (Nalge Nunc
International, New York, United States) were used for
immunochemical studies.
Transfection
The cultured cells were treated simultaneously with LPS
(1 g/ml) and several concentrations (1, 5, and 10 μM) of
ent-Sauchinone in 0.05% dimethyl sulfoxide (DMSO),
and the cells were harvested after 24 hours. For transient
transfection, cells were plated in 100-mm plates and
transiently transfected with STAT3 siRNA (Santa Cruz
Biotechnology Inc.) using the WelFect-EX PLUS reagent
in OPTI-MEN, according to the manufacturer’s specifica-
tion (WelGENE, Seoul, Korea).
Cell viability assay
The cytotoxicity of ent-Sauchinone was evaluated using
a WST-8 assay (Dojindo Laboratories, Tokyo, Japan).
WST-8 [2-(2-methoxy-4-nitrophenyl)-3(4-nitro-phenyl)-
5-(2,4-disulfo-phenyl)-2H-tetrazolium, monosodium salt]
is reduced by de-hydro-genases in cells to give a yellow-
colored product (formazan), which is soluble in the cul-
ture medium. The amount of the formazan dye generated
by the activity of dehydro-genases in cells is directly pro-
portional to the number of living cells. In brief, 1 × 104
cells (astrocytes and microglial BV-2 cells) per well were
plated into 96-well plates, incubated at 37°C for 24 hours,
and given a fresh change of medium. Cells were then incu-
bated in the DMEM media containing 10% FBS with or
without LPS (1 μg/ml) in the absence or presence of
various concentrations of ent-Sauchinone at 37°C for an
additional 24 hours. At that point, 10 μl of the WST-8
solution was added to the wells and incubation contin-
ued for another hour. The resulting color was assayed at
450 nm using a microplate absorbance reader (Sunrise®,
TECAN, Männedorf, Switzerland).
Determination of NO production
Cells were grown in 96-well plates and then incubated
with or without LPS (1 μg/ml) in the absence or presence
of various concentrations of ent-Sauchinone for 24 hours.
The nitrite accumulation in the supernatant was assessed
by the Griess reaction [21]. Each 50 μl of culture super-
natant was mixed with an equal volume of Griess reagent
[0.1% N-(1-naphthyl)-ethylenediamine, 1% sulfanilamide
in 5% phosphoric acid] and incubated at room temperature
for 10 minutes. The absorbance at 540 nm was measured
in a microplate absorbance reader and a series of known
concentrations of sodium nitrite was used as a standard.
Measurement of ROS
Generation of ROS was assessed by 2,7-dichlorofluores-
cein diacetate (DCFH-DA, Sigma-Aldrich), an oxidation
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molecular-weight peroxides can oxidize 2,7-dichloro-
fluorescein diacetate to the highly fluorescent compound
dichlorofluorescein (DCF). Briefly, astrocytes and microglial
cells were plated in 6-well plates (5 × 105), and subconfluent
cells were subsequently treated with ent-Sauchinone (1,
5, and 10 μM) for 30 minutes. After the cells were tryp-
sinized, 1 × 104 cells were plated in a black 96-well plate
and incubated with 10 μM DCFH-DA at 37°C for
4 hours. Fluorescence intensity of DCF was measured in
a microplate-reader at an excitation wavelength of 485 nm
and an emission wavelength of 538 nm.
Western blot analysis
Cells were homogenized with Protein Extraction Solution
(PRO-PREP®, Intron Biotechnology, Seongnam, Korea),
and lysed for 40 minutes incubation on ice. The lysate
centrifuged at 15,000 rpm for 15 minutes. Equal amount
of proteins (40 μg) were separated on a SDS/10%-poly-
acrylamide gel, and then transferred to a polyvinylidene
difluoride (PVDF) membrane (GE Water and Process
technologies, Trevose, Pennsylvania, United States). Blots
were blocked for 2 hours at room temperature with 5%
(w/v) non-fat dried milk in Tris-buffered saline tween-20
(TBST: 10 mM Tris (pH 8.0) and 150 mM NaCl solution
containing 0.05% tween-20). After a short wash in TBST
the membrane was incubated at room temperature with
specific antibodies. Rabbit polyclonal antibodies against
iNOS and COX-2 (1:1,000) (Cayman Chemical, Ann Arbor,
Michigan, United States), rabbit polyclonal antibodies
against p65 and IκB (1:500), and mouse monoclonal
antibody against p50 (1:500) (Santa Cruz Biotechnology
Inc. Santa Cruz, California, United States) were used in
the study. The blot was then incubated with the corre-
sponding conjugated anti-rabbit or mouse immunoglobu-
lin G-horseradish peroxidase (Santa Cruz Biotechnology
Inc.). Immunoreactive proteins were detected with the
enhanced chemiluminescence (ECL) western blotting
detection system.
Gel electromobility shift assay (EMSA)
Gel shift assays were performed according to the
manufacturer’s recommendations (Promega, Madison,
Wisconsin, United States). Briefly, 5 × 106 cells were washed
twice with 1 × PBS, followed by the addition of 1 ml of
PBS, and then the cells were scraped into a cold Eppen-
dorf tube. Cells were spun down at 13,000 rpm for 5 mi-
nutes and the resulting supernatant was removed. Cells
were suspended in 400 μl of solution A containing 10 mM
HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
dithiothreitol, and 0.2 mM phenylmethylsulfonyl fluoride;
vigorously vortexed; allowed to incubate on ice for 10 mi-
nutes; and centrifuged at 12,000 rpm for 6 minutes. The
pelleted nuclei were resuspended in solution C (solutionA+ 420 mM NaCl, 20% glycerol) and allowed to incubate
on ice for 20 minutes. The cells were centrifuged at
15,000 rpm for 15 minutes and the resulting nuclear
extract supernatant was collected in a chilled Eppendorf
tube. Consensus oligonucleotides were end-labeled
using T4 polynucleotide kinase and [γ-32P] adenosine
triphosphate (ATP) for 10 minutes at 37°C. Gel shift re-
actions were assembled and allowed to incubate at room
temperature for 10 minutes followed by the addition of
1 μl (50,000 to 200,000 cpm (Count per minute) of 32P
end-labeled oligonucleotide, followed by another 20 mi-
nutes of incubation at room temperature. Subsequently,
1 μl of gel loading buffer was added to each reaction
and loaded onto a 6% non-denaturing gel and electro-
phoresis until the dye was four-fifths of the way down
the gel. The gel was dried at 80°C for 1 hour and
exposed to film overnight at -70°C.
Secretase activities assay
β-secretase activity in BV-2 cells and astrocytes were
determined using a commercially available β-secretase
activity kit (Abcam, Inc, Cambridge, Massachusetts,
United States). Protein was extracted from cells using an
ice-cold extraction buffer, incubated on ice for 20 mi-
nutes and centrifuged at 10,000 rpm for 5 minutes at
4°C. The supernatant was collected. A total of 50 μL of
sample (total protein 100 μg) was added to each well
followed by 50 μL of 2 × reaction buffer and 2 μL of
β-secretase substrate incubated in the dark at 37°C for
2 hours. Fluorescence was read at excitation and emis-
sion wavelengths of 355 and 510 nm respectively, using
a Fluostar Galaxy fluorometer (BMG Lab Technologies,
Offenburg, Germany) with Felix software (BMG Lab
Technologies, Offenburg, Germany). β-secretase activity
is proportional to the fluorimetric reaction, and is expressed
as nmol/mg protein per minute.
Fluorescence microscopy
The fixed cells were exposed to the following primary
antibodies; GFAP, Iba1 and Aβ1-42 (1: 100 dilutions in
blocking serum, Cell Signaling Technology, Inc., Beverly,
Massachusetts, United States) at room temperature for
1 hour. After incubation, the cells were washed twice
with ice-cold PBS and incubated with an anti-rabbit or
mouse secondary antibody conjugated to Alexa Fluor
488 or 568 (Invitrogen-Molecular Probes, Carlsbad,
California, United States) at room temperature for 1 hour.
Immunofluorescence images were acquired using an
inverted fluorescent microscope Zeiss Axiovert 200 M
(Carl Zeiss, Thornwood, New York, United States).
Measurement of Aβ levels
Cell lysates (the same preparation of lysates as used for
western blotting) were obtained using a protein extraction
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benzene sulfonyl fluoride. Aβ1-42 levels were determined
using specific ELISAs (IBL, Immuno-Biological Laborator-
ies Co., Ltd., Fujioka, Japan). In brief, 100 μl of sample was
added to precoated plates and was incubated overnight at
4°C. After washing each well of the precoated plate with
washing buffer, 100 μl of labeled antibody solution was
added and the mixture was incubated for 1 hour at 4°C in
the dark. After washing, chromogen was added and
the mixture was incubated for 30 minutes at room
temperature in dark. Finally, the resulting color was
assayed at 450 nm using a microplate absorbance reader
(Sunrise®, TECAN, Männedorf, Switzerland) after the
addition of stop solution.
Pull-down assay
ent-Sauchinone was conjugated with cyanogen bromide
Epoxy-activated Sepharose 6B (Sigma, St Louis, Missouri,
United States). Briefly, ent-Sauchinone (1 mg) was
dissolved in 1 ml of coupling buffer (0.1 M NaHCO3
and 0.5 M NaCl, pH 6.0). The Epoxy-activated Sephar-
ose 6B was swelled and washed in 1 mM HCl on a
sintered glass filter, then washed with a coupling buffer.
Epoxy-activated Sepharose 6B beads were added to the
ent-Sauchinone containing coupling buffer and incu-
bated at 4°C for 24 hours. The ent-Sauchinone-conju-
gated Sepharose 6B was washed with three cycles of
alternating pH wash buffers (buffer 1: 0.1 M acetate and
0.5 M NaCl, pH 4.0; buffer 2: 0.1 M TriseHCl and 0.5 M
NaCl, pH 8.0). ent-Sauchinone-conjugated beads were
then equilibrated with a binding buffer (0.05 M Tri-
seHCl and 0.15 M NaCl, pH 7.5). The control unconju-
gated Epoxy-activated Sepharose 6B beads were
prepared as described above with the absence of ent-
Sauchinone. The cell lysate or STAT3 recombinant pro-
tein (Abnova, Taipei, Taiwan) were mixed with ent-Sau-
chinone conjugated Sepharose 6B or Sepharose 6B at 4
C for 24 hours. The beads were then washed three times
with TBST. The bound proteins were eluted with SDS
loading buffer. The proteins were then resolved by SDS-
PAGE followed by immunoblotting with antibodies
against STAT3 (1:1000 dilution, Santa Cruz Biotechnol-
ogy Inc.).
Molecular modeling
Docking studies between STAT3 and ent-Sauchinone
were performed using Autodock VINA [22]. STAT3 was
obtained from the X-ray crystal structure of dimeric
unphosphorylated STAT3 core fragment (PDB (Protein
Data Bank) ID: 3CWG) [23]. Only one monomer of the
homo-dimeric STAT3 crystal structure was used in the
docking experiments and conditioned using Autodock-
Tools by adding all polar hydrogen atoms. A three di-
mensional structure of ent-Sauchinone was built usingthe ChemBio3D (PerkinElmer Informatics, Massachuserrs,
United states) and Discovery Studio 3.5 Client (Accelrys,
Inc., California, United states), which was further prepared
using AutodockTools. The grid box was centered on the
STAT3 monomer and the size of the grid box was ad-
justed to include the whole monomer. Docking experi-
ments were performed at various exhaustiveness values of
the default, 16, 24, 32, 40, and 60.
Statistical evaluation
The data represent the mean ± S.E. of three independent
experiments performed in triplicate. Statistical analysis
was performed by one-way analysis of variance (ANOVA),
followed by a Dunnett test as a post hoc comparison.
Differences were considered significant at P <0.05.
Results
Effect of ent-Sauchinone on astrocyte and microglial BV-2
cell viability
Co-treatment with (1, 5, and 10 μM) ent-Sauchinone
and 1 μg/ml LPS resulted in a slight increase in the cell
viability of astrocytes (Additional file 1: Figure S1A) and
microglial BV-2 cells (Additional file 1: Figure S1B). Thus,
in this study, anti-inflammatory and anti-amyloidogenesis
effects were active with up to 10 μM of ent-Sauchinone.
Effect of ent-Sauchinone on LPS-induced ROS and NO
production, and iNOS and COX-2 expression in BV-2 cells
and astrocytes
To study the protective effect of ent-Sauchinone on LPS-
induced activation of astrocytes and microglial BV-2 cells,
the cells were treated with or without ent-Sauchinone in
the presence of LPS (1 μg/ml). Release of ROS and NO
was determined as an indicator of astrocyte and microglial
BV-2 cell activation as well as oxidative stress. We also
found that co-treatment of ent-Sauchinone reduced LPS-
(1 μg/ml) induced ROS in astrocytes (Figure 2A) and in
microglial BV-2 cells (Figure 2B), as well as NO gener-
ation in astrocytes (Figure 2C) and in microglial BV-2 cells
(Figure 2D). iNOS and COX-2 expression was then deter-
mined by western blot analysis since iNOS can be also
modulated by COX-2. As shown in Figure 2E and F, ex-
pression of iNOS and COX-2 was significantly lowered in
an unstimulated condition. However, iNOS and COX-2
expression was markedly increased in response to LPS
(1 μg/ml) after 24 hours. However, co-treatment with
ent-Sauchinone (1, 5, and 10 μM) caused a concentration-
dependent decrease of iNOS and COX-2 expression in
astrocytes (Figure 2E) and BV-2 cells (Figure 2F).
Effect of ent-Sauchinone on LPS-induced NF-κB DNA
binding activities
Activation of NF-κBis critical for the induction of inflam-
matory response genes, thus, we determined whether
Figure 2 Effect of ent-Sauchinone on LPS-induced ROS and NO release, protein expressions of iNOS and COX-2, and in astrocytes and
microglial BV-2 cells. Cells were treated with 1 μg/ml of LPS alone, or with LPS plus different concentrations (1, 5, and 10 μM) of ent-Sauchinone, at
37°C for 24 hours. Intracellular ROS levels were determined by measuring DCF fluorescence (A and B). NO level was determined by Griess reaction, as
described in Materials and Methods, in supernatants from astrocytes (C) and microglial BV-2 cells (D). Astrocytes (E) and microglial BV-2 cells (F) were
treated with 1 μg/ml of LPS alone, or with LPS plus different concentrations (1, 5, and 10 μM) of ent-Sauchinone, at 37°C for 24 hours. Equal amounts
of total protein (40 μg/lane) were subjected to 10% SDS-PAGE, and the expression of iNOS and COX-2 were detected by western blotting using
specific antibodies. β-Actin protein was used here as an internal control. *indicates significantly different from the control group (P <0.05). #indicates
significantly different from the LPS-treated group (P <0.05). Values below or above of each figures mean quantified relative expression of the proteins.
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LPS-activated BV-2 cells and astrocytes. BV-2 cells and
astrocytes were co-treated with LPS and ent-Sauchinone
for 60 minutes, which is the time needed to activate NF-
κB maximally (data not shown). Nuclear extracts from
co-treated cells were prepared and assayed NF-κB DNA
binding activity measured by EMSA. In astrocytes cells
(Figure 3A) and BV-2 cells (Figure 3B), co-treatment
with ent-Sauchinone inhibited LPS-induced NF-κB binding
activity in a concentration-dependent manner. The DNA
binding activity of NF-κB was confirmed with a supershift
assay with anti-p50 (Additional file 2: Figure S2A).
Effect of ent-Sauchinone on LPS-induced p50/p65
translocation and degradation of IKKα and IκB
Translocation of p50 and p65 as well as IκB degradation
is significant for the regulation of NF-κB. We examined
the nuclear translocation of p50 and p65 by western
blotting analysis. Nuclear translocation of p50 and p65
were inhibited by the co-treatment of ent-Sauchinone ina concentration-dependent manner in astrocytes and
BV-2 cells (Figure 3C and D). Next, we found that ent-
Sauchinone also inhibited the LPS-induced degradation
of IκB. (Figure 3C and D). These results indicate that
ent-Sauchinone inhibits the LPS-induced activation of
NF-κB via an inhibition of IκB phosphorylation as well
as the translocation of p50 and p65 into the nuclear.
When p50 and p65 subunits were phosphorylation, they
move into the nuclear.
Effect of ent-Sauchinone on LPS-induced amyloidogenesis
The effect of inflammation on amyloidogenesis in vitro
was also investigated since neuroinflammation can
cause amyloid generation and microglia and astrocytes
are a major source of neuroinflammation. Astrocytes
and microglia are both mechanical and metabolic sup-
ports to neurons, regulating the environment in which
they function. To determine the relationship between
neuroinflammation and amyloidogenesis, we investigated
whether the anti-inflammatory effect of ent-Sauchinone
Figure 3 Effects of ent-Sauchinone on NF-κB DNA binding activity and protein expressions of NF- κB in astrocytes and microglial BV-2
cells. Astrocytes (A) and microglial BV-2 cells (B) were treated with 1 μg/ml of LPS alone, or with LPS plus different concentrations (1, 5, and
10 μM) of ent-Sauchinone at 37°C for 1 hour. Activation of NF-κB was investigated using EMSA as described in Materials and Methods. Nuclear
extracts from astrocytes treated with LPS alone (1 μg/ml) or with ent-Sauchinone (1, 5, and 10 μM) and LPS were subjected to DNA binding
reaction with 32P end-labeled oligonucleotide specific to NF-κB. Specific DNA binding of the NF-κB complex is indicated by an arrow. Similar
results were obtained from at least three different sets of experiments. Equal amounts of nuclear extract (40 μg) were subjected to 10% SDS-PAGE.
Nuclear translocation of p50 and p65, and degradation of IKKα and IκB were detected by western blotting using specific antibodies. β-Actin protein
was used here as an internal control (C and D). Values represent the mean ± S.E. for three independent experiments performed in triplicate, and each
luciferase activity was calibrated using the amount of protein. Values above of each figure show the quantified relative expression of the proteins or
DNA binding activity.
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(Figure 4A), when unstimulated, the cells expressed low
levels of APP, site APP cleavage enzyme (BACE), and C99
protein, whereas the expressions of BACE and C99 pro-
teins increased in response to LPS (1 μg/ml) after 24 hours.
In addition, ent-Sauchinone also decreased LPS-induced
Aβ1–42 secretion into the culture media of astrocytes
(Figure 4C). Consistent with the expression of these
proteins, activation of β-secretases, which are the rate-
limiting enzymes in Aβ generation, was also increased
by LPS, but inhibited by ent-Sauchinone in a concentration-
dependent manner in astrocytes (Figure 4E and F). In micro-
glial BV-2 cells, we also found that ent-Sauchinone inhibited
LPS-induced expression of BACE1 and C99 (Figure 4B) as
well as the Aβ level in a concentration-dependent manner
(Figure 4D). Since activation of astrocytes is implicated inthe activation of β-secretase, we investigated whether the
numbers of activated (GFAP-positive) astrocytes and the
accumulation of Aβ (Aβ1–42-positive cells) were concomi-
tantly increased by LPS, and whether ent-Sauchinone
would reduce astrocyte activation, thereby reducing Aβ-
levels. To demonstrate this more clearly, cells immunore-
active for both GFAP and Aβ1–42 were identified using a
double immunofluorescence method. The co-reactive cell
number for both markers was markedly increased by LPS,
but was lowered by ent-Sauchinone treatment (Additional
file 3: Figure S3A). Moreover, to determine if treatment by
ent-Sauchinone inhibits LPS-induced amyloidogenesis, we
investigated the effects of ent-Sauchinone in another neu-
roglial cell type; microglial BV-2 cells. The co-reactive cell
number for both activation of microglia (Iba1-positive cells)
and Aβ accumulation (Aβ1-42-positive cells) was increased
Figure 4 Effect of ent-Sauchinone on expression of BACE1, C99, and Aβ1-42, β-secretase activity and Aβ1-42 level. Expressions of BACE1
and C99 were detected by western blotting using specific antibodies in astrocytes (A) and microglial BV-2 cells (B). Each blot is representative of
three experiments. β-Actin protein was used here as an internal control. Co-treatments with ent-Sauchinone and LPS for 24 hours were used.
Media were collected to determine Aβ1-42 secretion by ELISA from astrocytes (C) and microglial BV-2 cells (D). Values represent the mean ± S.E. of
three independent experiments with triplicate. The activities of β-secretasewere assessed using commercially available assay kits as described in
Materials and Methods (E and F). Values represent mean ± S.E. for three independent experiments performed in triplicate. *indicates significantly
different from the control group (P <0.05). #indicates significantly different from the LPS-treated group (P <0.05). Values above of each figure
mean quantified relative expression of the proteins.
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(Additional file 3: Figure S3B). These results further indi-
cate that the amyloidogenic pathway can be promoted by
neuro-inflammatory stimulation, and the anti-inflammatory
effect of ent-Sauchinone can result in anti-amyloidogenesis.
Effect of ent-Sauchinone on LPS-induced STAT3 activities
STAT3 cooperates with NF-κB in controlling the expres-
sion of genes contributing to inflammation and amy-
loidogenesis. Consistent with the inhibitory effect on
NF-κB activity, DNA binding activity of STAT3 elevated
by LPS was significantly reduced by ent-Sauchinone in
both astrocytes (Figure 5A) and microglial BV-2 cells
(Figure 5B). Astrocytes and microglial BV-2 cells were
treated with LPS (1 μg/ml) or co-treated with LPS and
ent-Sauchinone for 24 hours. LPS-induced STAT3activity (phosphorylation), which was markedly inhibited
by the co-treatment with ent-Sauchinone in astrocytes
and microglial BV-2 cells in a concentration-dependent
manner (Figure 5C and D). The DNA binding activity
of STAT3 was confirmed with a supershift assay with
anti-STAT3 (Additional file 2: Figure S2A).
Involvement of the STAT3 pathway in the inhibitory effect
of ent-Sauchinone on LPS-induced neuroinflammation
amyloidogenesis
To further examine the mechanisms regulating neuroin-
flammation and amyloidogenesis by STAT3 and NF-κB,
we used siRNA and a pharmacological inhibitor of
STAT3 in astrocytes and microglial BV-2 cells activated
by LPS, and investigated the participation of the STAT3
pathway in neuroinflammation and amyloidogenesis.
Figure 5 Effects of ent-Sauchinone on STAT3 DNA binding activity and protein expressions of STAT3 were detected by western
blotting using specific antibodies in astrocytes and microglial BV-2 cells. Astrocytes (A) and microglial BV-2 cells (B) were treated with
1 mg/ml of LPS alone or with LPS plus different concentrations (1, 5, and 10 μM) of ent-Sauchinone at 37°C for 1 hour. DNA binding activity of
STAT1 and STAT3 was investigated using EMSA as described in Materials and Methods. Nuclear extracts were subjected to DNA binding reaction
with 32P end-labeled oligonucleotide specific to STAT3. Specific DNA binding of the STAT3 complex is indicated by an arrow. Similar results were
treated with 1 μg/ml of LPS alone, or with LPS plus different concentrations (1, 5, and 10 μM) of ent-Sauchinone at 37°C for 1 hour. Equal
amounts of total proteins (40 μg/lane) were subjected to 10% SDS-PAGE, and activation of STAT3 (phosphorylation) was detected by western
blotting using specific antibodies in astrocytes (C) and in microglial BV-2 cells (D). Values below or above of each figures mean quantified relative
expression of the proteins or DNA binding activity.
Song et al. Journal of Neuroinflammation 2014, 11:118 Page 10 of 14
http://www.jneuroinflammation.com/content/11/1/118First, we examined the effectiveness of STAT3 siRNA on
pSTAT3 expression and BACE1 in cultured microglial
BV-2 cells, and found that knockdown with STAT3
siRNA completely abolished STAT3 expression as well
as BACE1 expression (Additional file 2: Figure S2B). ent-
Sauchinone inhibited Aβproduction and NF-κB activity
induced by LPS treatment in astrocytes. These inhibitory
effects were abolished by the downregulation of STAT3
expression with the pharmacological STAT3-specific in-
hibitor AG490 (50 μM) or with siRNA in cultured astro-
cytes (Figure 6A and C) and microglial BV-2 cells
(Figure 6B and D). These findings indicate that activa-
tion of STAT3 by ent-Sauchinone may not only inhibit
neuroinflammation but also prevent neuroinflammation-
induced Aβ production in astrocytes and microglial
BV-2 cells.
The interaction between ent-Sauchinone and STAT3
The interaction of ent-Sauchinone Sepharose 6B beads
with STAT3 recombinant protein or cell lysate contain-
ing STAT3 protein was assessed using a pull-down assay.
The interaction of ent-Sauchinone Sepharose 6B beads
with STAT3 was then detected by immunoblotting with
the anti-STAT3 antibody. The results indicated that ent-
Sauchinone interacted with recombinant STAT3 proteinor cell lysates containing STAT3 from microglial BV-2
cells (Figure 1B). To identity the binding site of ent-Sau-
chinone to STAT3, we performed computational docking
experiments with ent-Sauchinone and STAT3 (Figure 1C
and D). The binding study performed using Autodock
Vina software shows that ent-Sauchinone binds in a con-
cave binding pocket of STAT3 where three domains of the
DNA binding domain (DBD), the linker domain [24], and
the coiled-coil domain (CCD) all meet together. The bind-
ing pocket is composed of Gln247, Ala250, Cys251, Ile258,
Arg325, Pro333, and Pro336.
Discussion
Astrocytes and microglial cells play a key role in regulat-
ing the inflammation of the central nervous system
through the generation of NO, ROS, and other cyto-
kines. In this study, we investigated the inhibitory effects
of ent-Sauchinone on LPS-induced NO and ROS pro-
duction and expression of iNOS and COX-2 in BV-2
cells and astrocytes. ent-Sauchinone (1, 5, and 10 μM)
significantly inhibited LPS-induced NO and ROS pro-
duction in a concentration-dependent manner. These in-
hibitory effects may not be related to its cytotoxic effects
since no effects on cell viability were observed at con-
centrations of up to 10 μM in BV-2 cells and astrocytes.
Figure 6 Effects of inhibition of STAT3 on the effect of ent-Sauchinone on NF-κB activation and A level in cultured astrocytes and in
microglial BV-2 cells. To block the STAT3 pathway, cells were treated with the STAT3 inhibitor AG490 (50 μM) or with 50 nM siRNA for STAT3 for
1 hour prior to treatment with ent-Sauchinone. Abolished effect of STAT3 inhibition on the inhibitory effect of ent-Sauchinone on NF-κB DNA
binding activity in astrocytes (A) and microglial BV-2 cells (B), and A 1-42 level in astrocytes (C) and microglial BV-2 cells (D). For determination of
DNA binding activity of NF-κB and Aβ1-42 levels, cells were treated with 1 μg/ml of LPS alone, or with LPS plus different concentrations (1, 5, and
10 μM) of ent-Sauchinone at 37°C for 24 hours (1 hour for NF-κB) in the absence or presence of STAT3 inhibitor or siRNA. Values are mean ± S.E.
for three experiments performed in triplicate. *indicates significantly different from the control group (P <0.05). #indicates significantly different
from the LPS-treated group (P <0.05). & indicates significantly different from the LPS and ent-Sauchinone treated group (P <0.05). Values below
each figure mean quantified relative DNA binding activity.
Song et al. Journal of Neuroinflammation 2014, 11:118 Page 11 of 14
http://www.jneuroinflammation.com/content/11/1/118Comparison with the IC50 value of indomethacin
(53.8 μM, data not shown), a well-known non-steroidal
anti-inflammatory drug, in LPS-stimulated BV-2 cells
and astrocytes indicates that ent-Sauchinone has superior
effects on the inhibition of NO production [25,26].
This inhibitory effect on NO production could be re-
lated to the gene expression of iNOS and COX-2 since
ent-Sauchinone inhibited the iNOS protein in BV-2 cells
and astrocytes. These results showed that ent-Sauchinone
could interfere with LPS-induced inflammatory signaling
related to the production of pro-inflammatory molecules.
Since NF-κB is a critical transcriptional factor regulating
the expression of iNOS and COX-2, we examined the
effect of ent-Sauchinone on LPS-induced activation of
NF-κB. Consistent with the inhibitory effect on iNOS
and COX-2 expression, ent-Sauchinone inhibited NF-
κB-specific DNA binding activity in a concentration-
dependent manner. The promoter of the iNOS gene
contains two major discrete regions synergistically func-
tioning for the binding of transcription factors: one forNF-κB, which is mainly activated by LPS [27]. The pro-
moter of COX-2 has also one NF-κB consensus DNA
sequence. Therefore, inhibition of NF-κB activation
could be significantly related to the inhibitory effect of
ent-Sauchinone on iNOS and COX-2 expression. Sev-
eral studies have shown that anti-inflammatory agents
can inhibit NF-κB activity. Sesquiterpene lactones pre-
vented the activation of NF-κB resulting in the preven-
tion of inflammatory responses [28]. Lee et al. have also
demonstrated that 2’-hydroxy-cinnamaldehyde deacti-
vated NF-κB (p50) in the anti-inflammatory reaction in
macrophage RAW 264.7 cells [29]. We also found that
2,4-bis(p-hydroxyphenyl)-2-butenal inhibited LPS-induced
DNA binding activity of NF-κB in cultured astrocyte and
microglial BV-2 cells, thereby inhibiting neuroinflammation
[30]. Therefore, our data indicate that ent-Sauchinone
inhibits the expression of iNOS, COX-2, and NO and
ROS production by the inhibition of NF-κB activity, and
suggest that ent-Sauchinone may be useful as an anti-
inflammatory agent.
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cascades triggered by inflammatory stimuli such as LPS,
interferon gamma (IFNγ), and other cytokines [31]. STATs
in the cytoplasm translocate into the nucleus, where they
participate in the expression of many pro-inflammatory
genes [32]. There are several reports that STAT and NF-
κB interact with each other [33]. NF-κB and STAT regu-
late each other through regulation of cytokine production
[24]. In our study, consistent with the inhibition of NF-κB,
ent-Sauchinone also inhibited LPS-induced STAT3 activity
in astrocytes and microglial BV-2 cells. Moreover, STAT3
inhibition by siRNA and an inhibitor reversed the inhibi-
tory effects of ent-Sauchinone on LPS-induced NF-κB ac-
tivity. In a docking model, as well as a pull-down assay, we
found that ent-Sauchinone binds directly to STAT3 with a
binding affinity of approximately −7.9 to −8.6 Kcal/mol.
These findings indicate that inactivation of STAT3 by
ent-Sauchinone is significant to inhibit neuroinflamma-
tion in cultured astrocytes and microglial BV-2 cells.
It is noteworthy that neuroinflammation is associated
with the generation of Aβ in the brains of AD patients
[34]. We and other investigators found that systemic
LPS injection remarkably increases neuro-inflammatory
mediated amyloidogenesis [35]. Activated astrocytes and
microglia release molecules such as inflammatory cyto-
kines, ROS, and NO, which are known to induce BACE
expression, and thus stimulate Aβ regeneration [36,37].
In fact, we found that GFAP or Iba1 positive cells are re-
active for Aβ1-42, indicating that astrocytes and microglia
cells are at least responsible for Aβ generation while ent-
Sauchinone reduced these double reactive-cell numbers.
Therefore, the inhibitory effect of ent-Sauchinone on neu-
roinflammation in astrocytes and microglial BV-2 cells by
LPS might be associated with the reduction of amyloido-
genesis. It is also important to know that NF-κB controls
the expression of APP and BACE1, which enhances Aβ
formation [38], and we previously found that the activa-
tion of NF-κB contributes to the increase in β-secretase in
neuronal cells in vitro and in vivo [39]. It was also re-
ported that AD brains contain increased levels of both
BACE1 and NF-κB p65, and NF-κB p65 expression leads
to an increase in BACE1 promoter activity and BACE1
transcription, while knockout of NF-κB p65 decreases
BACE1 gene expression in cells [40]. It was also reported
that activation of STAT3, an important transcriptional
factor in inflammatory responses, is required for the up-
regulation of BACE1 transcription during amyloidogenic
processing of APP [18]. Thus, STAT3 may also play an
important regulatory role during neuroinflammation-
associated amyloidogenesis [41]. In this study, consistent
with the inhibitory effect on NF-κB, ent-Sauchinone
inhibited STAT3 activity. Moreover, STAT3 inhibition
by siRNA or an inhibitor reversed inhibitory effects of ent-
Sauchinone on LPS-induced Aβ generation and NF-κBactivity. Similar to these findings, our previous studies
showed that the inhibitory effect on NF-κB and/or
STAT3 DNA binding activity of thiacremonone, 4-O-
methylhonokiol, 2,4-bis(4-hydroxyphenyl)-2- butenal,
2,4-bis(4-hydroxyphenyl)-2- butenal diacetate and (−)-
epigallocatechin-3-gallate (EGCG) could be critical for the
anti-amyloidogenic effects of these compounds [42-47].
These results indicate that the blocking effect of ent-Sau-
chinone on NF-κB and STAT3 could contribute not only
to an anti-inflammatory effect but also amyloidogenic ef-
fects. These findings indicate that inactivation of STAT3-
mediated NF-κB by ent-Sauchinone may be significant in
inhibiting neuroinflammation and amyloidogenesis in cul-
tured astrocytes and microglial BV-2 cells.
We also found that ent-Sauchinone has good oral and
intestinal absorption as determined by the Caco-2 cell
permeability assay and human intestinal absorption (HIA)
rate. Several drug-likeness predictions such as Lipinski’s,
Lead-like, Comprehensive Medicinal Chemistry (CMC)-like,
and MACCS Drug Data ReportMDDR-like rules indicate
that this compound is suitable as a drug. ent-Sauchinone was
also evaluated as a non-mutagenic and non-carcinogenic
compound by the (Absorption, Distribution, Metabolism,
and Excretion (ADME)/Toxicity) test prediction program
(pre ADME version 1.0.2). Even though the efficacy and
potency of ent-Sauchinone are similar to other com-
pounds such as thiacremonone, 4-O-methylhonokiol, 2,
4-bis(4-hydroxyphenyl)-2- butenal, 2,4-bis(4-hydroxyphe-
nyl)-2- butenal diacetate, and (−)-epigallocatechin-3-gall-
ate (EGCG), the drug-like pharmacological properties of
ent-Sauchinone are superior to other compounds and it
can be obtained easily from nature. Thus, we believed
that this compound could be applicable for in vivo
study. Moreover, as neuroinflammation and amyloido-
genesis are critical for the development of Alzheimer’s
disease (AD), we will test the possible anti-AD effect of
ent-Sauchinone in an AD animal mice model. Taken
together, these data indicate that ent-Sauchinone could
be applicable for drug development for inflammatory
neurodegenerative diseases such as AD.Additional files
Additional file 1: Figure S1. Effect of ent-Sauchinone on viability of
astrocytes and microglial BV-2 cells. Cell viability was evaluated using a
WST-8 assay as described in Materials and Methods. Astrocytes (A) and
microglial BV-2 cells (B) were incubated with ent-Sauchinone (1, 5, and 10 μM)
in the absence of LPS for 72 hours. Results are given as a percentage of viable
cells related to untreated controls. The data represent the mean ± S.E. for three
independent experiments performed in triplicate. *indicates significantly
different from the control group (P <0.05). #indicates significantly different
from the LPS-treated group (P <0.05).
Additional file 2: Figure S2. Supershift assay and effect of STAT3 siRNA
on the expression of p-STAT3. (A) Supershift assay for NF-κB and STAT3
in the nuclear extract from cultured microglial BV-2 cells by anti-p50 and
STAT3. (B) Effect of STAT3 siRNA on the expression of p-STAT3 and BACE1
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http://www.jneuroinflammation.com/content/11/1/118in cultured microglial BV-2 cells. All the conditions were same as those in
Additional file 1: Figure S1.
Additional file 3: Figure S3. Expression of activation markers (GFAP for
astrocytes and Iba1 for microglia) and A 1–42 in astrocytes and in
microglial BV-2 cells, observed by double-fluorescence. Confocal
microscope observation was performed as described in Materials and
Methods. Cultured astrocytes were incubated with anti-GFAP and anti-A 1–42
primary antibodies (A), and the microglial BV-2 cells were incubated with
anti-Iba1 and anti-A 1–42 primary antibodies (B). Fluorescence was developed
using Alexa 568-conjugated anti-rabbit and Alexa 488-conjugated anti-mouse
secondary antibodies. Images of astrocytes double-labeled with GFAP
and A 1–42 (green) antibodies show the fluorescent antibody staining
separately and merged. Images of microglial BV-2 cells double-labeled
with Iba1 and A 1–42 (green) antibodies show the fluorescent antibody
staining separately and merged.
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